{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:18Z","timestamp":1740147258412,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015277","name":"Roche Products","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Emicizumab is a novel prophylactic medication used to treat patients with hemophilia A. It is indicated to minimize the frequency of bleeding episodes and the severity of serious bleeding in patients with hemophilia A utilizing inhibitors. However, some cases of bleeding episodes have been reported, and more data are needed regarding their management and expected outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report a case of a 4-year-old Saudi Arabian boy with severe hemophilia A who presented with a post-traumatic cerebral hemorrhage. The patient, with high titer inhibitors, was on emicizumab prophylaxis therapy. On hospital admission, he received tranexamic acid (10\u00a0mg intravenously, every 6\u00a0hours), and recombinant activated factor VII 120\u00a0\u00b5g\/kg every 2\u00a0hours for 2\u00a0days then every 4\u00a0hours for 4\u00a0days. On follow-up, the patient showed no signs of neurological deficit. There was no need for emergency neurosurgical intervention since the bleeding had been controlled throughout the first 2\u00a0days. There were no recorded thrombotic sequelae or neurological complications, with complete resolution within 10\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case implies that low-dose recombinant activated factor VII might be used safely and effectively with patients with hemophilia A on emicizumab prophylaxis, to reduce the risk of cerebral hemorrhage or another episode of serious bleeding along with its long-term complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03783-7","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T01:02:52Z","timestamp":1677114172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebellar hematoma in severe hemophilia with inhibitor on emicizumab prophylaxis: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-1919","authenticated-orcid":false,"given":"Sami","family":"Albattat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Alabdultaif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah","family":"Albattat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Batla","family":"Albattat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"unstructured":"World federation of hemophilia. Annual Global Survey 2020. 2020;96. https:\/\/wfh.org\/data-collection\/.","key":"3783_CR1"},{"issue":"6","key":"3783_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4103\/2231-0762.149022","volume":"4","author":"D Umar","year":"2014","unstructured":"Umar D, Baroudi K, Kaul R, Shastry S. Hemophilia A: dental considerations and management. J Int Soc Prevent Communit Dent. 2014;4(6):147.","journal-title":"J Int Soc Prevent Communit Dent"},{"issue":"9","key":"3783_CR3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","volume":"104","author":"G Castaman","year":"2019","unstructured":"Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702\u20139.","journal-title":"Haematologica"},{"issue":"14","key":"3783_CR4","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.3390\/ijms22147647","volume":"22","author":"EC Rodr\u00edguez-Merch\u00e1n","year":"2021","unstructured":"Rodr\u00edguez-Merch\u00e1n EC, De Pablo-Moreno JA, Liras A. Gene therapy in hemophilia: recent advances. IJMS. 2021;22(14):7647.","journal-title":"IJMS"},{"issue":"7","key":"3783_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ajh.24777","volume":"92","author":"R Kruse-Jarres","year":"2017","unstructured":"Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et\u00a0al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695\u2013705.","journal-title":"Am J Hematol."},{"issue":"11","key":"3783_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fimmu.2020.00476","volume":"24","author":"S Merlin","year":"2020","unstructured":"Merlin S, Follenzi A. Escape or fight: inhibitors in hemophilia A. Front Immunol. 2020;24(11):476.","journal-title":"Front Immunol"},{"issue":"12","key":"3783_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/2040620717737701","volume":"8","author":"M Giansily-Blaizot","year":"2017","unstructured":"Giansily-Blaizot M, Schved JF. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther Adv Hematol. 2017;8(12):345\u201352.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"3783_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1055\/s-0040-1714279","volume":"120","author":"G Gelbenegger","year":"2020","unstructured":"Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the missing link with emicizumab: a bispecific antibody for treatment of hemophilia A. Thromb Haemost. 2020;120(10):1357\u201370.","journal-title":"Thromb Haemost"},{"issue":"9","key":"3783_CR9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, et\u00a0al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"3783_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.thromres.2010.04.004","volume":"126","author":"S Butenas","year":"2010","unstructured":"Butenas S, Parhami-Seren B, Undas A, Fass DN, Mann KG. The \u201cnormal\u201d factor VIII concentration in plasma. Thromb Res. 2010;126(2):119\u201323.","journal-title":"Thromb Res"},{"issue":"9","key":"3783_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1111\/jth.15419","volume":"19","author":"A Abdi","year":"2021","unstructured":"Abdi A, Eckhardt CL, van Velzen AS, Vuong C, Coppens M, Castaman G, et\u00a0al. Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: a case\u2013control study. J Thromb Haemost. 2021;19(9):2171\u201381.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"3783_CR12","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","volume":"10","author":"S Lacroix-Desmazes","year":"2020","unstructured":"Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: recent progress. Front Immunol. 2020;10(10):2991.","journal-title":"Front Immunol"},{"issue":"3","key":"3783_CR13","first-page":"249","volume":"12","author":"TC Singleton","year":"2012","unstructured":"Singleton TC, Keane M. Diagnostic and therapeutic challenges of intracranial hemorrhage in neonates with congenital hemophilia: a case report and review. Ochsner J. 2012;12(3):249\u201353.","journal-title":"Ochsner J"},{"issue":"5","key":"3783_CR14","first-page":"378","volume":"17","author":"E Zanon","year":"2019","unstructured":"Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus. 2019;17(5):378\u201384.","journal-title":"Blood Transfus"},{"doi-asserted-by":"publisher","unstructured":"Gulati D, Dua D, Torbey MT. Hemostasis in Intracranial Hemorrhage. Front Neurol. 2017;8. https:\/\/doi.org\/10.3389\/fneur.2017.00080\/full.","key":"3783_CR15","DOI":"10.3389\/fneur.2017.00080\/full"},{"issue":"03","key":"3783_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0040-1717114","volume":"121","author":"C Schmitt","year":"2021","unstructured":"Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, et\u00a0al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost. 2021;121(03):351\u201360.","journal-title":"Thromb Haemost"},{"issue":"Supplement_1","key":"3783_CR17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood-2019-126659","volume":"134","author":"KL Zimowski","year":"2019","unstructured":"Zimowski KL, Batsuli GM, Bryant P, McDaniel J, Tickle K, Meeks SL, et\u00a0al. Severe bleeding events in hemophilia \u0391 patients receiving emicizumab prophylaxis. Blood. 2019;134(Supplement_1):1126\u20131126.","journal-title":"Blood"},{"doi-asserted-by":"crossref","unstructured":"Abarca-Villaseca V, Soto-Arellano V. Breakthrough bleeding episodes at minimum and improvement in quality of life in a child with severe hemophilia A with inhibitors treated with emicizumab: a case report from Chile. Am J Case Rep. 2021;22. Available from: https:\/\/www.amjcaserep.com\/abstract\/index\/idArt\/929598.","key":"3783_CR18","DOI":"10.12659\/AJCR.929598"},{"doi-asserted-by":"publisher","unstructured":"Barg AA, Avishai E, Budnik I, Levy\u2010Mendelovich S, Barazani TB, Kenet G, et\u00a0al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors\u2014a single\u2010center cohort. Pediatr Blood Cancer. 2019;66(11). https:\/\/doi.org\/10.1002\/pbc.27886.","key":"3783_CR19","DOI":"10.1002\/pbc.27886"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03783-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03783-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03783-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T01:04:20Z","timestamp":1677114260000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03783-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3783"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03783-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"28 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethical committee of the institution. Written informed consent was obtained from the parents for the publication of this case report and accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient's\u00a0parents for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}